Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, randomized pivotal Phase 3 study of selinexor in combination with ruxolitinib versus placebo in combination with ruxolitinib JAKi treatment-naïve patients with myelofibrosis

Next Previous
Trial Profile

Double-blind, randomized pivotal Phase 3 study of selinexor in combination with ruxolitinib versus placebo in combination with ruxolitinib JAKi treatment-naïve patients with myelofibrosis

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary) ; Selinexor (Primary)
  • Indications Myelofibrosis
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 18 Apr 2023 According to a Karyopharm Therapeutics media release, the company expect to initiate this trial later this quarter.
  • 18 Apr 2023 According to a Karyopharm Therapeutics media release, Dr. Mascarenhas will describe the design of this trial in the webcast the study's primary investigator.
  • 16 Jan 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top